drugset / Trial / NCT00363896

A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

NCT00363896

Phase 3 Completed 843 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.

Timeline

Start
2006-07
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Aclidinium Small molecule 200 ug Inhaled